Each material 8-K filed by a company listed on a US stock exchange (NYSE, Nasdaq, Cboe), read and summarized: what happened, the key numbers, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). This page lists the last 45 days; every brief stays on its company's 8-K page (1654 companies, A–Z).
Immunovant reported that IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 in Period 2 of a potentially registrational trial in difficult-to-treat rheumatoid arthritis, with FDA discussions planned later this year on the path forward. The company also said it is unlikely to advance IMVT-1402 further in Sjogren's disease beyond the ongoing Phase 2 trial, while its net loss narrowed and cash declined over the period.
IMVT-1402 600 mg ACR20 response at Week 28 was 92.5% vs. 75.6% for placebo (p=0.0139); the 300 mg arm did not differ from placebo.
FDA discussions are planned for later this year on the registrational program in difficult-to-treat rheumatoid arthritis.
Net loss for the quarter ended September 30, 2026 was $97.2 million ($0.47 per share), vs. $126.5 million ($0.73 per share) a year earlier; cash and equivalents were $722.3 million, down from $902.1 million at March 31, 2026.
AST SpaceMobile said it will build its own 20-ton rocket, named Blacklift, to launch BlueBird satellites, starting in late 2028. It will pay about $800 million upfront for a license to make Firefly's Miranda and Vira engines and $500 million under a supply and services agreement. The filing gives no revenue, profit, or guidance figures, so its effect on financial results cannot be measured from this document.
Upfront license consideration of about $800 million: $400 million in cash plus 10 to 14 million Class A shares, based on a forward VWAP calculation
Supply and services agreement: $250 million for engines for the first three Blacklift launches and $250 million for engineering support over three years
Blacklift is designed for up to five BlueBird satellites per launch, with launches starting in late 2028
Company will host a Blacklift unveiling event on Thursday, November 12 in New York City
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Frequently asked questions
Which filings get a brief?
Form 8-K filings by companies listed on a US stock exchange (NYSE, Nasdaq, Cboe; not over-the-counter stocks) that report a material event: results (Item 2.02), deals (1.01, 2.01), executive changes (5.02), restructuring (2.05), impairments (2.06), delisting notices (3.01), restatements (4.02), cybersecurity incidents (1.05), bankruptcy (1.03) and Regulation FD or other events (7.01, 8.01). Routine filings such as vote results or exhibits only are skipped.
How is the impact score set?
The AI rates each filing from 1 (routine) to 5 (major, such as a merger, bankruptcy or restatement) based only on what the filing says. It is a reading aid for sorting the day's filings, not a prediction of how the stock will move.
How quickly do briefs appear?
On weekdays the SEC filing feed is checked every 5 minutes from 6 am to 5:45 pm Eastern, when nearly all 8-Ks come in, and every hour after that until 10 pm. Briefs of the 1,000 largest companies follow within minutes; the others usually within the hour, or later the same day when many filings arrive at once.
Which companies are covered?
Every company with shares listed on the NYSE, Nasdaq or Cboe that files 8-Ks, about 4,500 of them. Foreign companies that report on Form 6-K instead are not included. The S&P 1500 only filter above narrows the list to the large, mid and small caps of the S&P Composite 1500.
Are older briefs kept?
Yes. This page shows the last 45 days, but every brief ever published stays online: each has its own page, and each company has an 8-K page listing all of its briefs, newest first, linked from its stock page and from the A-Z list of companies.